IL140982A0 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
IL140982A0
IL140982A0 IL14098299A IL14098299A IL140982A0 IL 140982 A0 IL140982 A0 IL 140982A0 IL 14098299 A IL14098299 A IL 14098299A IL 14098299 A IL14098299 A IL 14098299A IL 140982 A0 IL140982 A0 IL 140982A0
Authority
IL
Israel
Prior art keywords
coadministration
acat
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
IL14098299A
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL140982A0 publication Critical patent/IL140982A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
IL14098299A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions IL140982A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
IL140982A0 true IL140982A0 (en) 2002-02-10

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14098299A IL140982A0 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291L (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (en) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Prevention of plaque rupure by ACAT inhibitors
DOP2000000107A (en) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS
EP1237862A1 (en) * 1999-12-17 2002-09-11 Versicor, Inc. Succinate compounds, compositions and methods of use and preparation
AU2001282541B2 (en) * 2000-09-01 2004-06-24 Sankyo Company, Limited Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
NZ536116A (en) * 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
KR101011373B1 (en) * 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
ES2191762T3 (en) * 1995-08-04 2003-09-16 Warner Lambert Co USE OF DERIVATIVES OF SULFAMIC ACID, ACIL SULFONAMIDS OR SULFONIL CARBAMATES FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REDUCE LEVELS OF LIPOPROTEINS.
SK282863B6 (en) * 1996-05-17 2002-12-03 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
CA2256716A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
JP2002521328A (en) 2002-07-16
HRP20010055A2 (en) 2002-04-30
NO20010291D0 (en) 2001-01-18
CZ2001126A3 (en) 2002-01-16
EA200100153A1 (en) 2001-08-27
YU3501A (en) 2005-06-10
AU4701799A (en) 2000-02-14
NO20010291L (en) 2001-01-18
BR9912296A (en) 2001-04-17
EE200100046A (en) 2002-06-17
WO2000004892A3 (en) 2000-05-18
SK502001A3 (en) 2002-06-04
CA2335062A1 (en) 2000-02-03
CN1310629A (en) 2001-08-29
KR20010083134A (en) 2001-08-31
ZA200100294B (en) 2002-01-10
PL346011A1 (en) 2002-01-14
AP2001002035A0 (en) 2001-03-31
WO2000004892A2 (en) 2000-02-03
TR200100205T2 (en) 2001-05-21
ID30030A (en) 2001-11-01
BG105162A (en) 2001-12-29
IS5809A (en) 2001-01-12
EP1098662A2 (en) 2001-05-16
HUP0102880A2 (en) 2002-06-29
HUP0102880A3 (en) 2002-11-28
OA11584A (en) 2004-07-20

Similar Documents

Publication Publication Date Title
GB9800795D0 (en) Prevention of multiple use of limited use devices
EP1100392A4 (en) Methods and devices for reducing the mineral content of vascular calcified lesions
AU3034300A (en) Substituted benzimidazoles and their use as parp inhibitors
HUP0101613A3 (en) Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
AU2212299A (en) Compositions and methods for the treatment of tumor
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
PL341335A1 (en) Combination of ace and mmp inhibitors
HU9802971D0 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
GB2342045B (en) Mineral and vitamin combinations for the treatment of stress and allergies
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
PL346011A1 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
HK1041827B (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the same
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
IT1302811B1 (en) PROCEDURE AND RELATED APPARATUS FOR DIRECT REDUCTION OF IRON OXIDES
EP0964686A4 (en) Methods and compositions for preventing or retarding the development of atherosclerotic lesions
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL143212A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
NO20004920D0 (en) Use of protease inhibitors for the treatment of skin damage
GB9823036D0 (en) Fluticasone lotion having improved vasoconstrictor activity
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
AU1940800A (en) Combination therapy for the treatment of sepsis
AU1292000A (en) Device and method for the direct reduction of iron oxides